N/A
N=27
Strategies for Treating Anxiety Research Study
Anxiety Disorders · Anxiety
Bottom Line
View on ClinicalTrials.gov: NCT05398016 ↗Enrolled (actual)
27
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. — 17 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- low-intensity intervention for anxiety (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Nevada, Las Vegas
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. |
17 | — |
| PRIMARY Change in Anxiety Symptoms |
4.69 | — |
| PRIMARY Change in Avoidance |
6.68 | — |
| PRIMARY Sustained Change in Anxiety Symptoms |
4.75 | — |
| SECONDARY Acceptability of Intervention Measure (AIM) |
4.88 | — |
| SECONDARY Feasibility of Intervention Measure (FIM) |
5 | — |
| SECONDARY Implementation Appropriateness Measure (IAM) |
4.88 | — |
| SECONDARY World Health Organization's Disability Assessment Schedule 2.0 (WHODAS 2.0) |
4.600 | — |
Summary
This single-arm pilot clinical trial will evaluate the feasibility, acceptability, and engagement of target mechanism, and preliminary impact of a low-intensity behavioral intervention for mild-to-moderate anxiety disorders. Treatment will delivered by trained lay counselors ("coaches;" n = 5-6) to 2-5 patient participants each depending on enrollment and scheduling (n = up to 25).
Eligibility Criteria
Inclusion Criteria
- age ≥ 18 years,
- score on Beck Anxiety Inventory (BAI) ≥ 16,
- ability to speak English
- willing and able to attend in-person study visits at UNLV
- community dwelling
Exclusion Criteria
- other psychological conditions rendering the person unlikely to benefit from a brief treatment, including psychosis, bipolar disorder, cognitive impairment, and substance abuse or dependence (comorbid depression permitted);
- active suicidal ideation or intent;
- concurrent receipt of regular individual psychotherapy;
- use of anxiolytic medication.
Data sourced from ClinicalTrials.gov (NCT05398016). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.